Abstract:AbstractBackgroundThe role of neuroinflammation in the pathogenesis of Alzheimer’s disease (AD) is still controversial. Recent studies proposed that microglial response may have a stage‐dependent effect on disease progression. Considering the CSF soluble triggering receptor expressed on myeloid cells 2 (sTREM2) has emerged as a promising marker of microglial activation, we aimed to further test this hypothesis by studying the association between baseline sTREM2 with dynamic brain structural changes in different stage of AD.Method22 amyloid‐positive (A+) and tau‐positive (T+) AD patients and 24 A+T+ MCI patients were identified from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The patients had baseline measurements of CSF A‐beta, P‐Tau, sTREM2, baseline and follow‐up T1‐weighted and diffusion tensor imaging (DTI) scans, and were followed up for at least one year. Voxel‐based morphometry (VBM) analysis was performed to assess grey matter volumetric change, while fractional anisotropy (FA) and mean diffusivity (MD) were derived from DTI scans to evaluate white matter microstructural integrity. Linear mixed effect models were then applied to model the longitudinal change of grey and white matter integrity, and to analyze the influence of baseline sTREM2 on the rate of brain structural changes.ResultIn A+T+ AD patients, baseline CSF sTREM2 was associated with faster FA decline and MD increase in association fibers including corpus callosum, inferior longitudinal fasciculus, cingulum, inferior fronto‐occipital fasciculus, and superior longitudinal fasciculus. In A+T+ MCI patients, baseline CSF sTREM2 was associated slower grey matter volumetric loss in regions including Alzheimer’s signature cortices such as angular gyrus and precuneus, while mixed findings were found regarding white matter integrity, with a protective effect with regard to MD but a potential negative effect against FA values in association fibers.ConclusionThe current study suggests that microglial activation at early AD stage might have a protective effect against neurodegeneration, while at late stage, it might facilitate neurodegenerative process. These observations support the hypotheses that microglial response is an active factor in the process of Alzheimer’s pathogenesis, and that it has stage‐dependent effects on disease progression. Future efforts on modulating microglial activation could be promising, given a carefully selected time window for intervention.

Evidence for reduced anti-inflammatory microglial phagocytic response in late-life major depression

Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Microglial Reactivity Correlates with Presynaptic Loss Independent of β‐Amyloid and Tau

Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease

The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults

Potential Inflammatory Markers Related to the Conversion to Alzheimer's Disease in Female Patients With Late-Life Depression

Different inflammatory signatures based on CSF biomarkers relate to preserved or diminished brain structure and cognition

Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease

Proteogenomic signature of risk of Alzheimer's disease and related dementia risk in individuals with a history of major depression disorder

Association between Cerebrospinal Fluid sTREM2 Levels and Depression: The Alzheimer's Disease Neuroimaging Initiative Study

Preliminary evidence for preserved synaptic density in late-life depression

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

Microglial activation occurs late during preclinical Alzheimer's disease

Microglial Activation and Connectivity in Alzheimer Disease and Aging

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

CSF Strem2 Has Opposite Association with Brain Structural Damage Rate at Early and Late Stage of Alzheimer’s Disease

Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression